@just_drewh's one-year Wegovy journey, fact-checked

What did @just_drewh actually say?

The creator announced their one-year anniversary on Wegovy, reporting a starting weight of 214 pounds and a current weight of 151 pounds. That works out to 63 pounds lost over 52 weeks, roughly 1.2 pounds per week on average. They described the experience as "a journey full of triumphs and challenges" and credited community support as part of what got them there. No dose, no dietary protocol, no exercise regimen was mentioned. This is a personal experience video, not medical advice, and the creator doesn't frame it as such. That framing matters when we evaluate what's worth taking seriously here and what needs more context.

Does the science back this up?

A 63-pound loss over one year on semaglutide is plausible, but it sits above average clinical trial outcomes. Yes, it's within range, but it's toward the high end. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found participants on 2.4 mg semaglutide lost an average of 14.9 percent of body weight over 68 weeks. For someone starting at 214 pounds, that average would be roughly 31 to 32 pounds. Sixty-three pounds represents about 29.4 percent of starting body weight, nearly double the trial average. That doesn't mean it's impossible. Individual variation in response to GLP-1 receptor agonists is real and well-documented. Some participants in STEP 1 lost more than 20 percent. Dietary changes and physical activity, both of which this creator hints at through the workout hashtag, substantially amplify outcomes. But calling this a typical Wegovy result would be inaccurate.

What did they get wrong (or right)?

Credit where it's due: the creator didn't promise anyone else these results. They didn't say "you'll lose 60 pounds too" or "Wegovy cured me." That restraint is genuinely refreshing compared to a lot of GLP-1 content on TikTok. What's missing, and this matters, is any acknowledgment that their results are well above average. Viewers watching this video are almost certainly benchmarking against it. When someone with 13,800 views shares a 63-pound loss with no context about how unusual that is, the implicit message is that this is what Wegovy does. It isn't, necessarily. The STEP 5 trial (Garvey et al., 2022, Nature Medicine) confirmed long-term efficacy but also showed weight regain accelerates sharply when the medication is discontinued. None of that nuance appears here, and its absence is a real gap for viewers making decisions.

What should you actually know?

Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition. It works by mimicking GLP-1, a hormone that regulates appetite and slows gastric emptying. Clinical results are real, but they vary considerably by individual. The STEP program trials consistently showed that the drug works best alongside behavioral changes. Wilding et al. (2021) noted that participants who combined semaglutide with lifestyle intervention saw the strongest outcomes. Side effects, including nausea, vomiting, and gastrointestinal distress, affect a significant portion of users, particularly in the dose-escalation phase. Anyone considering Wegovy should have that conversation with a licensed clinician, not a TikTok comment section. Personal transformation stories can be motivating, but they are not clinical evidence of what your individual outcome will look like.

The bottom line

This video is honest in what it claims: one person's experience over one year. The reported weight loss of 63 pounds is within the biological range of what semaglutide can do, but it meaningfully exceeds average clinical trial outcomes. The creator deserves credit for not overpromising. But viewers deserve to know that results this dramatic are not the median. If this video is your primary data point for what to expect from Wegovy, you're missing most of the picture. Talk to a clinician who can look at your specific health profile before drawing conclusions from someone else's one-year recap.